Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

Authors:	Darren R Feldman MD Yasser Ged MBBS Chung-Han Lee PhD Andrea Knezevic MS Ana M Molina MD Ying-Bei Chen PhD Joshua Chaim DO Devyn T Coskey MS Samuel Murray MS Satish K Tickoo MD Victor E Reuter MD Sujata Patil PhD Han Xiao MD Jahan Aghalar MD Arlyn J Apollo MD Maria I Carlo MD Robert J Motzer MD Martin H Voss MD

Institution:	1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York;2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York;3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York;4. Department of Medicine, Weill Cornell Medical College, New York, New York;5. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York;6. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York;7. Department of Medicine, Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey;8. Department of Medicine, Memorial Sloan Kettering Cancer Center, Commack, New York;9. Department of Medicine, Memorial Sloan Kettering Cancer Center, Center at Rockville Center, Woodmere, New York

Abstract:

Keywords:	bevacizumab everolimus genomics papillary RCC RCC